Bullish all the way!_老虎社区_美港股上老虎

Angellaq
2021-05-10

Bullish all the way!

BioNTech EPS beats by €1.33, beats on revenue

(May 10) BioNTech SE (BNTX) (Nasdaq: BNTX, “BioNTech” or “the Company”) a next generation immunother

BioNTech EPS beats by €1.33, beats on revenue

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":190453245,"tweetId":"190453245","gmtCreate":1620646856387,"gmtModify":1631890466784,"author":{"id":3583404232736853,"idStr":"3583404232736853","authorId":3583404232736853,"authorIdStr":"3583404232736853","name":"Angellaq","avatar":"https://static.tigerbbs.com/819ba48990e156eed8f64aae01bf2650","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":6,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":4,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Bullish all the way!&nbsp;</p></body></html>","htmlText":"<html><head></head><body><p>Bullish all the way!&nbsp;</p></body></html>","text":"Bullish all the way!","highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":3,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/190453245","repostId":1173680926,"repostType":4,"repost":{"id":"1173680926","pubTimestamp":1620646501,"share":"https://www.laohu8.com/m/news/1173680926?lang=&edition=full","pubTime":"2021-05-10 19:35","market":"us","language":"en","title":"BioNTech EPS beats by €1.33, beats on revenue","url":"https://stock-news.laohu8.com/highlight/detail?id=1173680926","media":"seekingalpha","summary":"(May 10) BioNTech SE (BNTX) (Nasdaq: BNTX, “BioNTech” or “the Company”) a next generation immunother","content":"<p>(May 10)&nbsp;BioNTech SE (BNTX) (Nasdaq: BNTX, “BioNTech” or “the Company”) a next generation immunotherapy company pioneering novel therapies for cancer and infectious diseases, today provided an update on its corporate progress and reported financial results for the quarter ended March&nbsp;31, 2021.</p><ul><li>BioNTech(NASDAQ:BNTX): Q1 GAAP EPS of&nbsp;€4.39beats by €1.33.</li><li>Revenue of €2.05B (+7300.7% Y/Y)beats by €270M.</li><li>More than 450 million doses of BNT162b2 supplied to 91 countries or territories worldwide as of May 6, 2021</li><li>Signed agreements for over 1.8 billion doses of BNT162b2 in 2021 and first contracts signed for periods 2022 and beyond</li><li>Announced planned expansion of global footprint toAsiawith establishment of first regional headquarters for south eastAsiainSingapore, including a fully-integrated and state-of-the art mRNA manufacturing facility</li><li>In oncology, a first-in-human Phase 1 trial started for the neoantigen-targeting T cell therapy, BNT221. The development of BioNTech’s oncology pipeline has continued to accelerate with 14 product candidates now in 15 ongoing trials.</li></ul><p>BioNTech rose more than 8% in premarket trading.</p><p><img src=\"https://static.tigerbbs.com/f3a48b0a57f38d7cf3070a5a14b83d2b\" tg-width=\"789\" tg-height=\"523\" referrerpolicy=\"no-referrer\"></p><p><b>First quarter 2021 financial results (unaudited)</b></p><p><b>Revenues: </b>Total revenues were estimated to be €2,048.4&nbsp;million1for the three months ended March 31, 2021, compared to €27.7&nbsp;million for the three months ended March 31, 2020. The increase was mainly due to rapidly increasing the supply of COVID-19 vaccine worldwide. Under the collaboration agreements, territories have been allocated between BioNTech, Pfizer and Fosun Pharma based on marketing and distribution rights. BioNTech’s commercial revenues include an estimated amount of €1,751.9&nbsp;million1comprising BioNTech’s share of gross profit from COVID-19 vaccine sales in Pfizer’s territories, which represents a net figure, as well as sales milestones. In addition, €63.9&nbsp;million sales to BioNTech’s collaboration partners of products manufactured by BioNTech and €199.8&nbsp;million direct COVID-19 vaccine sales to customers in BioNTech’s territory have been recognized.</p><p><b>Cost of Sales: </b>Cost of sales were estimated to be €233.1&nbsp;million1for the three months ended March 31, 2021, compared to €5.9&nbsp;million for the three months ended March 31, 2020. Estimated cost of sales of €223.2&nbsp;million1were recognized with respect to BioNTech’s COVID-19 vaccine sales and include Pfizer’s share of gross profits earned by BioNTech.</p><p><b>Research and Development Expenses: </b>Research and development expenses were €216.2&nbsp;million for the three months ended March 31, 2021, compared to €65.1&nbsp;million for the three months ended March 31, 2020. The increase was mainly due to an increase in research and development expenses for BioNTech’s BNT162 program, recorded as purchased services with respect to those expenses, which were initially incurred by Pfizer and subsequently charged to BioNTech under the collaboration agreement. The increase was further driven by an increase in wages, benefits and social security expenses from increasing headcounts and recognizing expenses incurred under the new share-based-payment arrangements.</p><p><b>General and Administrative Expenses:</b> General and administrative expenses were €38.9&nbsp;million for the three months ended March 31, 2021, compared to €15.8&nbsp;million for the three months ended March 31, 2020. The increase was mainly due to higher expenses for professional services, an increase in wages, benefits and social security expenses from increasing headcounts and recognizing expenses incurred under the new share-based-payment arrangements as well as higher insurance premiums.</p><p><b>Income Taxes: </b>Interim income taxes were €514.2&nbsp;million for the first quarter of 2021 and were recognized using the estimated annual effective income tax rate of approximately 31%.</p><p><b>Net Profit / (Loss): </b>Net profit was €1,128.1&nbsp;million for the three months ended March 31, 2021, compared to €53.4&nbsp;million net loss for the three months ended March 31, 2020.</p><p><b>Cash Position: </b>Cash and cash equivalents as of March 31, 2021 were €891.5&nbsp;million.</p><p><b>Shares Outstanding: </b>Shares outstanding as of March 31, 2021 were 241,521,065.</p><p><b>Update on current signed COVID-19 vaccine order book:</b></p><p>Estimated COVID-19 vaccine revenues&nbsp;to BioNTech&nbsp;upon delivery of currently signed supply contracts of ~1.8&nbsp;billion doses is ~€12.4&nbsp;billion.</p><p>This revenue estimate reflects:</p><ul><li>Expected revenues from direct COVID-19 vaccine sales to customers in BioNTech’s territory</li><li>Expected revenues from sales to collaboration partners of products manufactured by BioNTech</li><li>Expected sales milestone payments from collaboration partners</li><li>Expected revenues related to share of gross profit from COVID-19 vaccine sales in the collaboration partners’ territories</li></ul><p>Additional revenues related to further supply contracts for deliveries in 2021 expected with first contracts in place for 2022 and beyond.</p><p>Full year 2021 manufacturing capacity now targeting 3 billion doses and more than 3 billion doses for the year 2022.</p><p><b>On Track with Previously Stated 2021 Financial Outlook:</b></p><p><img src=\"https://static.tigerbbs.com/18224adc0e1a84aacccba6f816c54aa8\" tg-width=\"617\" tg-height=\"371\" referrerpolicy=\"no-referrer\"></p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BioNTech EPS beats by €1.33, beats on revenue</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBioNTech EPS beats by €1.33, beats on revenue\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-10 19:35 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3693691-biontech-eps-beats-by-133-beats-on-revenue><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(May 10) BioNTech SE (BNTX) (Nasdaq: BNTX, “BioNTech” or “the Company”) a next generation immunotherapy company pioneering novel therapies for cancer and infectious diseases, today provided an update ...</p>\n\n<a href=\"https://seekingalpha.com/news/3693691-biontech-eps-beats-by-133-beats-on-revenue\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE"},"source_url":"https://seekingalpha.com/news/3693691-biontech-eps-beats-by-133-beats-on-revenue","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1173680926","content_text":"(May 10) BioNTech SE (BNTX) (Nasdaq: BNTX, “BioNTech” or “the Company”) a next generation immunotherapy company pioneering novel therapies for cancer and infectious diseases, today provided an update on its corporate progress and reported financial results for the quarter ended March 31, 2021.BioNTech(NASDAQ:BNTX): Q1 GAAP EPS of €4.39beats by €1.33.Revenue of €2.05B (+7300.7% Y/Y)beats by €270M.More than 450 million doses of BNT162b2 supplied to 91 countries or territories worldwide as of May 6, 2021Signed agreements for over 1.8 billion doses of BNT162b2 in 2021 and first contracts signed for periods 2022 and beyondAnnounced planned expansion of global footprint toAsiawith establishment of first regional headquarters for south eastAsiainSingapore, including a fully-integrated and state-of-the art mRNA manufacturing facilityIn oncology, a first-in-human Phase 1 trial started for the neoantigen-targeting T cell therapy, BNT221. The development of BioNTech’s oncology pipeline has continued to accelerate with 14 product candidates now in 15 ongoing trials.BioNTech rose more than 8% in premarket trading.First quarter 2021 financial results (unaudited)Revenues: Total revenues were estimated to be €2,048.4 million1for the three months ended March 31, 2021, compared to €27.7 million for the three months ended March 31, 2020. The increase was mainly due to rapidly increasing the supply of COVID-19 vaccine worldwide. Under the collaboration agreements, territories have been allocated between BioNTech, Pfizer and Fosun Pharma based on marketing and distribution rights. BioNTech’s commercial revenues include an estimated amount of €1,751.9 million1comprising BioNTech’s share of gross profit from COVID-19 vaccine sales in Pfizer’s territories, which represents a net figure, as well as sales milestones. In addition, €63.9 million sales to BioNTech’s collaboration partners of products manufactured by BioNTech and €199.8 million direct COVID-19 vaccine sales to customers in BioNTech’s territory have been recognized.Cost of Sales: Cost of sales were estimated to be €233.1 million1for the three months ended March 31, 2021, compared to €5.9 million for the three months ended March 31, 2020. Estimated cost of sales of €223.2 million1were recognized with respect to BioNTech’s COVID-19 vaccine sales and include Pfizer’s share of gross profits earned by BioNTech.Research and Development Expenses: Research and development expenses were €216.2 million for the three months ended March 31, 2021, compared to €65.1 million for the three months ended March 31, 2020. The increase was mainly due to an increase in research and development expenses for BioNTech’s BNT162 program, recorded as purchased services with respect to those expenses, which were initially incurred by Pfizer and subsequently charged to BioNTech under the collaboration agreement. The increase was further driven by an increase in wages, benefits and social security expenses from increasing headcounts and recognizing expenses incurred under the new share-based-payment arrangements.General and Administrative Expenses: General and administrative expenses were €38.9 million for the three months ended March 31, 2021, compared to €15.8 million for the three months ended March 31, 2020. The increase was mainly due to higher expenses for professional services, an increase in wages, benefits and social security expenses from increasing headcounts and recognizing expenses incurred under the new share-based-payment arrangements as well as higher insurance premiums.Income Taxes: Interim income taxes were €514.2 million for the first quarter of 2021 and were recognized using the estimated annual effective income tax rate of approximately 31%.Net Profit / (Loss): Net profit was €1,128.1 million for the three months ended March 31, 2021, compared to €53.4 million net loss for the three months ended March 31, 2020.Cash Position: Cash and cash equivalents as of March 31, 2021 were €891.5 million.Shares Outstanding: Shares outstanding as of March 31, 2021 were 241,521,065.Update on current signed COVID-19 vaccine order book:Estimated COVID-19 vaccine revenues to BioNTech upon delivery of currently signed supply contracts of ~1.8 billion doses is ~€12.4 billion.This revenue estimate reflects:Expected revenues from direct COVID-19 vaccine sales to customers in BioNTech’s territoryExpected revenues from sales to collaboration partners of products manufactured by BioNTechExpected sales milestone payments from collaboration partnersExpected revenues related to share of gross profit from COVID-19 vaccine sales in the collaboration partners’ territoriesAdditional revenues related to further supply contracts for deliveries in 2021 expected with first contracts in place for 2022 and beyond.Full year 2021 manufacturing capacity now targeting 3 billion doses and more than 3 billion doses for the year 2022.On Track with Previously Stated 2021 Financial Outlook:","news_type":1},"isVote":1,"tweetType":1,"viewCount":384,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":17,"xxTargetLangEnum":"ORIG"},"commentList":[],"hasMoreComment":false,"orderType":2}

BioNTech EPS beats by €1.33, beats on revenue

评论（3）

热议股票